The tumor growth curve showed a trend consistent with the longitudinal bioluminescence assay, indicating significant early-stage inhibition of tumor growth in the BsAb-treated group compared with that in the PBS-, PD-1 scFv- and TREM2 scFv-treated groups (Fig. 3D and Fig. S3A-D). Here, TREM2 is linked to neoplasm.